ReviewJournal of clinical research in pediatric endocrinology2017
The Rationale for Growth Hormone Therapy in Children with Short Stature.
Review in Journal of clinical research in pediatric endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Effects of growth hormone therapy on facial anthropometric features in children with growth disorders: a cohort study.Annals of medicine and surgery (2012) · 2026Article
- Genetic screening of the insulin-like growth factor 1 receptor gene in children born small for gestational age: the continuing importance of insulin-like growth factor 1 signaling.Endocrine journal · 2026Article
- Optimal final adult height achieved by low-dose recombinant human growth hormone therapy.Asian biomedicine : research, reviews and news · 2024Article
- Stimulation of skeletal stem cells in the growth plate promotes linear bone growth.JCI insight · 2024Article
- Use of connected injection device has a positive effect on catch-up growth in patients with growth disorders treated with growth hormone therapy.Frontiers in endocrinology · 2024Article
- Review
- Frequency of oligosymptomatic gastrointestinal tract diseases and its relation to insulin-like growth factor I in idiopathic (non-GH-deficient) short stature children.Archives of medical science : AMS · 2021Article
- Lack of Catch-Up Growth with Growth Hormone Treatment in a Child Born Small for Gestational Age Leading to a Diagnosis of Noonan Syndrome with a PathogenicCase reports in endocrinology · 2021Article
- Real-World Treatment Patterns and Outcomes of Growth Hormone Treatment Among Children in Israel Over the Past Decade (2004-2015).Frontiers in pediatrics · 2021Article
- Quantitative ultrasound screening of bone mineral density on children with short stature.Saudi medical journal · 2020Article
- Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone TherapyJournal of clinical research in pediatric endocrinology · 2019Review
- Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1.Frontiers in endocrinology · 2019Article
- Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.Frontiers in endocrinology · 2018Review
- Prevalence of Endocrine Disorders in Childhood Brain Tumor Survivors in South Korea.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH) was first isolated from cadaver pituitary glands, requiring laborious and expensive collection of glands, followed by extraction and purification of the hormone. This limited supply restricted its use to children with severe GH deficiency who were treated with low dosages and suboptimal schedules. The development of recombinant DNA-derived GH, allowed the production of virtually unlimited amounts of GH, leading to the approval for therapy for a large number of childhood conditions characterized by non-GH deficient short stature. The aim of this review is to provide a critical overview on the daily use of GH in two paradigmatic conditions of non-GH deficient short stature which are children born small for gestational age and with idiopathic short stature, highlighting the available strength of evidence for efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.